(CLB)

Reporting relationship: SVP & CFO
Issuer ticker: CLB
Reported as of: 12 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Feb 2026, 11:04:01 UTC
Prior SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Tattoli, Attorney-in-Fact

Key filing fact

Christopher Scott Hill filed Form 4 for Core Laboratories Inc. /DE/ (CLB) on 17 Feb 2026.

Key facts

This page summarizes Christopher Scott Hill's Form 4 filing for Core Laboratories Inc. /DE/ (CLB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Feb 2026, 11:04.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001641315 Primary reporting owner

Hill Christopher Scott

Relationship: SVP & CFO
Address: 6316 WINDFERN ROAD, HOUSTON
Signature: /s/ Mark Tattoli, Attorney-in-Fact
Signature date: 17 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLB holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 59
Date: 12 Feb 2026
Ownership: 401(k) Plan
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLB transaction Derivative

Performance Shares

Award

Transaction value: $0
Shares: +70,008
Change %
Price: $0.000000
Shares after: 70,008
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,008
Exercise price: $0.000000
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Reporting Person's indirect beneficial ownership includes 59 shares of the Issuer's common stock held in the Issuer's 401(k) plan, which were previously reported but were inadvertently omitted from a prior Form 4 filing.

Footnote F2

This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period.

Footnote F3

The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period.